We undertook a study to identify the vestibular and hearing abnormalities associated with phenytoin toxicity. Since October 1977, 23 patients with phenytoin toxicity have been referred to the Department of Otorhinolaryngology by the Department of Neurology for electrooculographic (EOG) evaluation. (There have been no cases ofserious phenytoin toxicity seen in our department since August 1989.) In addition to EOG, all patients had undergone otoscopic, audiometric, and neurologic examinations. We found that the most common pathologic findings detected by EOG were abnormalities in pursuit tracking. The most common signsfound on clinical exploration were cerebellar dysfunction and facial palsy. EOG findings in patients with phenytoin toxicity are compatible with cerebellar disease.
Introduction
Phenytoin (diphenylhydantoin) is one of the most widely used anticonvulsants, particularly in the acute and chronic management of epilepsy in children and adults. This drug is remarkably free of serious side effects,' although toxic blood levels can cause adverse neurotologic effects.' Long-term therapy has been reported to cause cerebellar atrophy in humans.' Adverse effects in experimental animals have included a loss of Purkinje,s cells, edema of Bergmann's glial cell layer, anddegenerative cell changes.' From The primary signs and symptoms of toxicity are shown in table 1. 1 ,5-13 Generally, all these effects are reversible and disappear after a reduction in dosage or cessation of the drug, except for chronic cerebellar ataxia secondary to long-term phenytoin intake, which is considered to be irreversible. ' The aim of our study was to identify the vestibular and hearing abnormalities associated with phenytoin toxicity.
Materials and methods
Since October 1977, 23 patients with phenytoin toxicity have been referred to the Department of Otorhinolaryngology by the Department of Neurology for electrooculographic (EOG) evaluation. (There have been no cases of serious phenytoin toxicity seen in our department since August 1989.) The diagnosis of phenytoin toxicity had been made in the Department of Neurology according to the presence of certain clinical manifestations (table 2) . According to our retrospective chart review, the 15 female and 8 male patients ranged in age from 13 to 64 years (mean: 34.6). Otoscopy, audiometry, a basic neurologic exploration, and an EOG examination had been performed on all subjects. Since 1985, it has been possible to obtain blood phenytoin levels at our hospital, and this information was included in the records of 8 In one subject with lupus erythematosus receiving concomitant multiple drug therapy, a highly elevated ALT level was noted affer the fourth week of cevimeline therapy. Intwoother subjects receiving cevimeline intheclinical trials, very high AST levels were noted. The significance ofthese findings isunknown. Additional adverse events (relationship unknown) which occurred in other clinical studies (patient popuiation different lromSjogren's patients) are asfollows: cholinergic syndrome, blood pressure Iluctuation, cardiomegaly, postural hypotension, aphasia, convulsions, abnormal gait, hyperesthesia, paralysis, abnormal sexual function, enlarged abdomen, change in bowel habits, gum hyperplasia, intestinal obstruction, bundle branch block, increased creatine phosphokinase, electrolyte abnormality, glycosuria, gout, hyperkalemia, hyperproteinemia, increased lactic dehydrogenase (LDH), increased alkaline phosphatase, failure to thrive, abnormai platelets, aggressive reaction, amnesia, apathy, delirium, delusion, dementia, illusion, impotence, neurosis, paranoid reaction, personality disorder, hyperhemoglobinemia, apnea, atelectasis, yawning, Oliguria, urinary retention, distended vein, lymphocytosis MANAGEMENT OF OVERDOSE: Management otthe signs and symptoms of acute overdosage should be handled ina manner consistent with that indicated for other muscarinic agonists: general supportive measures should be instituted. It medically indicated, atropine, ananti-cholinergic agent may be of value asanantidote foremergency use in patients who have had an overdose of cevimeline. If medically indicated, epinephrine may also beofvalue inthepresence of severe cardiovascular depression or bronchoconstriction. It is notknown if cevimeline is dialyzable. DOSAGE ANO ADMINISTRATION: The recommended dose ofcevimeline is30mgtaken three times aday. There is insufficient safety information to support doses greater than 30mgtid.There Isalso insufficient evidence foradditional efficacy ofcevimeline atdoses greater than 30mgtid. Drug Inleraclions: Cevimeline should beadministered with caution to patients taking beta adrenergic antagonists, because ofthepossibility of conduction disturbances. Drugs with parasympathomimetic effects administered concurrently with cevimeline can beexpected to have additive effects. Cevimeline might interfere with desirable antimuscarinic effects ofdrugs used concomitantly. Drugs which inhibit CYP2D6 and CYP3A3/4 also Inhibit the metabolism of cevimeline. Cevimeline should beused with caution in individuals known orsuspected to be deficient InCYP2D6 activity, based onprevious experience, asthey may beatahigher riskofadverse events. Inaninvitro study, cytochrome P450 isozymes lA2,2A6, 2C9, 2C19, 206, 2El,and 3M were notinhibited byexposure to cevlmeline. Carcinogenesis, Mulagenesis andImpairment 01 Fertility: Lifetime carcinogenicity studies were conducted inCD-l mice and F-344 rats. Astatistically significant Increase Inthe Incidence of adenocarcinomas ofthe uterus was observed infemale rats that received cevimeline atadosage of100 mg/kg/day (approximately 8 times themaximum human exposure based oncomparison ofAUC data). Noother significant differences intumor incidence were observed in either mice orrats. Cevimeline exhibited noevidence ofmutagenicity orclastogeniclty inabattery ofassays thatincluded anAmes test, anin vitro chromosomal aberration study inmammalian cells, a mouse lymphoma study InL5178Y cells, oramicronucleus assay conducted invivo in leRmice.
Cevlmeline didnotadversely affect thereproductive performance orfertility of male Sprague-Dawley rats when administered for63days prior to mating and throughout theperiod ofmating atdosages upto 45mg/kg/day (approximately 5 times themaximum recommended dose fora60kghuman following normalization ofthedata onthe basis of body surface area estimates). Females thatwere treated with cevlmellne atdosages upto 45mglkg/day from 14days prior to mating through day seven of gestation exhibited astatistically significantly smaller number ofimplantations than did control animals. Pregnancy: Pregnancy Category C. Cevimeline was associated with a reduction inthe mean number ofimplantations when given to pregnant Sprague-Dawley rats from 14days prior to mating through day seven ofgestation atadosage of45mg/kg/day (approximately 5 times themaximum recommended dose fora60kghuman when compared onthebasis of body surface area estimates). This effect may have been secondary to maternal tOXicity. There are noadequate and well-controlled studies Inpregnant women. Cevimellne should beused during pregnancy only If thepotential benefit justifies the potential risk to thefetus. Nursing Mothers: It isnotknown whether thisdrug is secreted Inhuman milk. Because many drugs are excreted in human milk, and because ofthepotential forserious adverse reactions innursing Infants from EVOXACTM, adecision should be made whether to discontinue nursing ordiscontinue thedrug, taking into account theimportance ofthe drug to themother. Pedialric Use: Safety and effectiveness Inpediatric patients have notbeen established. Gerialric Use: Although clinical studies of cevimeline included SUbjects over theage of65,thenumbers were notsufficient todetermine whether they respond differently trom younger subjects. Special care should beexercised when cevimeline treatment isinitiated inanelderly patient, considering the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease orother drug therapy intheelderly. ADVERSE REACTIONS: Cevimeline was administered to 1777 patients during clinical trials worldwide, including Sjogren's patients and patients with other conditions. Inplacebo-controlled Sjogren's studies inthe U.S., 320 patients received cevimeline doses ranging from 15mgtidto 60mgtid,ofwhom 93% were women and 7%were men. Demographic distribution was 90% Caucasian, 5%Hispanic, 3%Black, and 2% of other origin. Inthese studies, 14.6% of patients discontinued treatment with cevimeline due toadverse events. The following adverse events associated with muscarinic agonism were observed intheclinical trials ofcevimeline in Sjogren's syndrome patients:
Cevimellne and vertical nystagmic components. Each patient was evaluated for saccades, spontaneous nystagmus, response to rotational and positional tests, vestibulo-ocular reflex suppression, optokinetic nystagmus, and pursuit tracking. Saccades were studied with an alternating luminous point that was driven by an OK4 generator (ServoMed). Spontaneous nystagmus was registered with closed eyes. Rotational tests were conducted with a diminished pendular stimulus; at the same time, vestibulo-ocular reflex suppression was registered with the patient's gaze fixed on a point that moved simultaneously with the pendular motion. Optokinetic nystagmus was stimulated with a rotating drum that was electrically controlled at two different speeds: 30 0 and 150 0/sec. All results were analyzed by the Department of Research at our institution. 
Results
We found no hearing impairment in any of these patients. The most common clinical findings were cerebellar signs and facial palsy. On EOG, the most common pathologic findings were abnormalities in pursuit tracking. We saw no case of diplopia or impairment of the IIIrd, TV", or Vl" cranial nerves. Details:
• Inthe charts of the 8 patients who were seen after 1985, the only information with respect to blood phenytoin levels was whether levels were higher than 30 ug/ml. Therefore, it was not possible to calculate statistical correlations between blood levels and vestibular responses.
Eight cases were revised 1 year later, and all of these patients had the same EOG findings that they had during their first exploration.
Discussion
Phenytoin use is remarkably free of complications. 1 Reports of serious side effects, including mental symptoms and seizures, have usually been confined to patients who took a single large dose, either accidentally or intentionally. Deaths have been reported occasionally in adults" and children.P:" In patients who do have high serum phenytoin levels, nystagmus appears at a concentration of about 20 ug/ml and ataxia at 30 ug/ml." Today, toxicity is rare because we have a better understanding of phenytoin's pharmacologic characteristics. For example, although there is great variability in neurologically and neurotologically toxic serum levels, there have been no cases of serious toxicity in our department since 1989. This fact underscores the clear improvement in our clinical management of phenytoin.
The most common finding in our series was alteration in pursuit tracking. However, no conclusions regarding typical oculomotor findings have been reported in the current literature because of the small number of cases reported in each article.?" To our knowledge, no large series has been reported to date.
Videonystagmography is the current method of choice for evaluating ocular movements in the neurotologic practice. EOG examination was employed in this study because these patients had been evaluated before videonystagmography had become completely developed. Although we were not able to' obtain quantitative measurements of alterations in ocular movement, we believe that qualitative findings also have great clinical value.
On the basis of experimental data, the structure of the central nervous system that is most affected by phenytoin poisoning is the cerebellum.' Our EOG findings of cerebellar dysfunction support this hypothesis. The evidence for cerebellar damage is supported by two experimental findings: (1) the increase in the postsynaptic potentials produced by gamma aminobutyric acid in the vestibulooculomotor system and (2) the increase in the rate of Purkinje's cell discharge at the cerebellar flocculus." Deficits in some cranial nerves (V and VII) can also occur, so facial paralysis and impairment of the Vth cranial nerve are not considered to be rare in phenytoin toxicity.
Audiometric alterations (presbyacusis) are not linked to phenytoin toxicity, and hearing does not appear to be affected by toxic phenytoin levels. Neither of these findings has been previously reported. Unlike Manlapaz," we found no case of abducens nerve palsy in our patients.
Ever since the first reports of phenytoin toxicity, dialysis (peritoneal and/or hemodialysis) and bed rest have been advocated as a useful treatment. 18 Although death associated with phenytoin toxicity is rare, the possibility justifies such aggressive management.l':"
